Table 2.

Patient treatment and response data

Infusion samples
PatientCells × 109%TCR positiveaTCR + %CD4TCR + %CD8%TCR + 1 monthbTumor responsecSerum inhibitionAntibody binding
2107836540.9NRNoNo
39.88713822.6NRNoYes
44.69711780.7NRYesYes
59.99121806.6NRNoNo
65.8776891.6NRNoNo
71.883405634NRNoNo
819.455445332NRNoNo
92.38444561.5NRNoNo
1168.89759677CRNoNo
1246.585208225NRNoNo
131109029743NRNoNo
145492118819PRYesYes
1594.18916783NRNoNo
1639.190187911PRNoYes
17609759537NRNoNo
1955.8nd1388ndNRNoYes
200.83733590.05NRNoNo
211.24540543.96NRNoNo
222.24212810.12NRNoNo
2315531644.16NRNoNo
240.55177154.6PRNoNo
252.13329631.72NRNoNo
260.85231564.35NRYesYes
2727.7855941.71NRNoNo
289.2783940.41NRNoNo
293.7774040ndNRNoNo

NOTE: Patients 2–19 treated with gp100:154 TCR-transduced cells; 20–29 treated with p53 TCR-transduced cells.

Abbreviations: TCR, T-cell receptor; NR, no response; PR, partial response; CR, complete response; nd, no data.

  • aCD3-positive cell population.

  • bCD8-positive cell population.

  • cRECIST criteria.